ROSA MARÍA
AYALA DÍAZ
Profesora titular de universidad
Hospital Ramón y Cajal
Madrid, EspañaPublications in collaboration with researchers from Hospital Ramón y Cajal (25)
2024
-
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
Cancer, Vol. 130, Núm. 20, pp. 3436-3451
2023
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Disease markers, Vol. 2022, pp. 3132941
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
-
The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
Frontiers in Oncology, Vol. 12
2021
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
2020
-
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity
British Journal of Haematology, Vol. 189, Núm. 4, pp. 672-683
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2019
-
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
Haematologica, Vol. 104, Núm. 2, pp. 288-296
-
Immediate effects of dasatinib on the migration and redistribution of naïve and memory lymphocytes associated with lymphocytosis in chronic myeloid leukemia patients
Frontiers in Pharmacology, Vol. 10
2018
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098
2017
2016
-
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Haematologica, Vol. 101, Núm. 8, pp. 926-931
-
Leucemia mieloide crónica en España: sus características de presentación han cambiado. Sección española del registro poblacional EUTOS
Revista Clinica Espanola, Vol. 216, Núm. 6, pp. 293-300
2015
-
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Annals of Hematology, Vol. 94, Núm. 6, pp. 911-918